London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash.

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney.

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million in ...

The trial is scheduled to commence in the fourth quarter of this year, with subject recruitment in both Europe and the US.

Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first to take a gene therapy for a kidney disease into the clinic. The money ...

This is the first time such results have been achieved in both children and adult patients born with a specific type of ...

A Northeast Ohio woman and a 22-year-old man from UAE are among the first patients to receive the innovative CRISPR treatment.

From birth to gene-edited in 6 months: Custom therapy breaks speed limits The N-of-1 accomplishment provides a template for swift, personalized genetic therapies.

Purespring’s platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and ...

Despite the immense potential of gene therapies, drugmakers have soured on the field. So an ambitious charity is trying to step in.

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.